SCHEMBL3263288

SCHEMBL3263288

CCCCCNc1nc2ccccc2cc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.52
TLR8 Q9NR97 1/20 0.51
SOAT1 P35610 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
KDM4E B2RXH2 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GBA1 P04062 1/20 0.49
TRIM58 Q8NG06 1/20 0.48
S1PR2 O95136 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FGFR1 P11362 1/20 0.47
KDR P35968 1/20 0.47
TOP2A P11388 3/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
STAT1 P42224 1/20 0.46
RAB9A P51151 1/20 0.46
PDE5A O76074 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28962063 0.82 KMT2A (0.48) ACP1TLR8SOAT1NPSR1KDM4E
SCHEMBL28962071 0.77 KMT2A (0.54) NPSR1KDM4EL3MBTL1GBA1LMNA
SCHEMBL28426308 0.77 TLR8 (0.73) ACP1TLR8NPSR1KDM4EL3MBTL1
SCHEMBL3263464 0.75 TLR8 (0.48) ACP1TLR8NPSR1KDM4EL3MBTL1
SCHEMBL29103979 0.74 TLR8 (0.51) TLR8SOAT1KDM4EL3MBTL1ALDH1A1
SCHEMBL5393759 0.73 TLR8 (0.59) ACP1TLR8NPSR1KDM4ES1PR2
SCHEMBL27459127 0.72 TLR8 (0.58) TLR8NPSR1KDM4EGBA1TRIM58
SCHEMBL27512057 0.72 TLR8 (0.58) TLR8NPSR1KDM4EGBA1TRIM58
SCHEMBL4866807 0.72 ACP1 (0.89) ACP1NPSR1GBA1S1PR2LMNA
SCHEMBL28962059 0.71 TLR8 (0.53) ACP1TLR8NPSR1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C ACP1 3477/4885TLR8 3013/4885SOAT1 4265/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C ACP1 3477/4885TLR8 3013/4885SOAT1 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.